![]() Instead, an ADA-accessible bus stop will be created on Meridian Street South at Max Luther Drive. Route 7īuses will no longer turn around in the parking lot of the County Health Department on Max Luther Drive. Access paratransit will continue to provide door-to-door service. Instead, ADA-accessible bus stops will be created (both northbound and southbound) on Markaview Road. Route 3 will no longer drive through the parking lots at Clearview Cancer Institute and the Huntsville VA Clinic off Markaview Road. The proposed modifications are as follows: Route 3 15, 2024, and only affect fixed-route buses. The proposed changes will go into effect Jan. “Public comments help guide our efforts to make Huntsville Transit a safe and efficient service for all, no matter where you live or where you’re heading.” “We appreciate all those who came out and provided feedback at our last meetings in October,” said Quisha Bryant, Director of Huntsville’s Parking and Public Transportation Department. 13, at the Transfer Station Platform, 500B Church St., Huntsville. The public can view maps, learn more about the proposed changes and provide feedback to Huntsville Transit officials. River Forest, Illinois, United States, 60305Įdward H.Huntsville Transit patrons are invited to upcoming public meetings to provide comments about proposed modifications to four routes. West Suburban Medical Center- River Forest Naperville, Illinois, United States, 60540 Orange City, Florida, United States, 32763 Midland Florida Clinical Research Center, L ![]() Jacksonville, Florida, United States, 32256 Stamford, Connecticut, United States, 06902 San Francisco, California, United States, 94143 Redlands, California, United States, 92373 Los Angeles, California, United States, 90017 Huntsville, Alabama, United States, 35805Ĭompassionate Cancer Care Medical Group - Incįountain Valley, California, United States, 92708 Note: Other protocol defined Inclusion/Exclusion criteria may apply.īirmingham, Alabama, United States, 35243 Active serious infections requiring anti-microbial therapy.Myocardial infarction or unstable angina pectoris within 6 months of enrollment or history of serious ventricular arrhythmia (ie, ventricular tachycardia or ventricular fibrillation), high-grade atrioventricular block, or other cardiac arrhythmias or Left ventricular ejection fraction (LVEF) of Individuals with known germline breast cancer gene (BRCA) mutations.Prior treatment with topoisomerase 1 inhibitors or antibody-drug conjugates (ADCs) containing a topoisomerase inhibitor.Evidence of recurrent disease following preoperative therapy and surgery.Prior treatment with another stimulatory or coinhibitory T-cell receptor agent (eg, cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), OX-40, cluster of differentiation 137 (CD137), prior treatment with any HER2-directed agent.Stage IV (metastatic) breast cancer as well as history of any prior (ipsi- or contralateral) invasive breast cancer.Individuals must have received appropriate radiotherapy and have recovered prior to starting study treatment.Eastern Cooperative Oncology Group (ECOG) performance status 0-1.Submission of both pre-neoadjuvant treatment diagnostic biopsy and resected residual invasive disease tissue.Adequate excision and surgical removal of all clinically evident of disease in the breast and/or lymph nodes and have adequately recovered from surgery. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |